Bringing the Oncology Community Together
Bevacizumab Receives Priority Review in Ovarian Cancer
The FDA has assigned a priority review designation to bevacizumab (Avastin) in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.
Immunotherapy Combination Receives Breakthrough Designation for Pancreatic Cancer
The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.
Dabrafenib/Trametinib Extends OS Versus Vemurafenib in Phase III Melanoma Trial
A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis
Lanreotide Improves PFS in Patients With Neuroendocrine Tumors
The somatostatin analog lanreotide (Somatuline Depot) significantly prolonged progression-free survival (PFS) compared with placebo for patients with metastatic gastroenteropancreatic neuroendocrine tumors.
FDA Grants Priority Review to Bevacizumab in Advanced Cervical Cancer
The FDA has assigned a priority review designation to bevacizumab (Avastin) plus chemotherapy as a treatment for patients with persistent, recurrent, or metastatic cervical cancer.
Risk of Recurrence Low in Small, HER2-Positive Breast Tumors
Patients with small, node-negative, HER2-positive breast cancer tumors had a low risk of invasive recurrence after 5 years
Vemurafenib/Cobimetinib Extends PFS in Phase III Melanoma Study
The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved PFS compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.